Lars B. Abrahmsen - 10 Mar 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Reporting relationship: SVP, Chief Scientific Officer
Issuer ticker: APRE
Reported as of: 10 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Mar 2022, 17:01:04 UTC
Prior SEC filing: 05 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Scott M. Coiante, attorney-in-fact

Key filing fact

Lars B. Abrahmsen filed Form 4 for Aprea Therapeutics, Inc. (APRE) on 14 Mar 2022.

Key facts

This page summarizes Lars B. Abrahmsen's Form 4 filing for Aprea Therapeutics, Inc. (APRE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Mar 2022, 17:01.

Change

Previous filing in this sequence was filed on 05 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APRE transaction

Common Stock

Award

Transaction value: $0
Shares: +24,700
Change %: +130%
Price: $0.000000
Shares after: 43,700
Date: 10 Mar 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APRE transaction Derivative

Stock Option (right to Buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 10 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $1.82
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Footnote F2

Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.